The search result changed since you submitted your search request. Documents might be displayed in a different sort order.
  • search hit 10 of 18
Back to Result List

Formation, signaling and occurrence of specialized pro-resolving lipid mediators - what is the evidence so far?

  • Formation of specialized pro-resolving lipid mediators (SPMs) such as lipoxins or resolvins usually involves arachidonic acid 5-lipoxygenase (5-LO, ALOX5) and different types of arachidonic acid 12- and 15-lipoxygenating paralogues (15-LO1, ALOX15; 15-LO2, ALOX15B; 12-LO, ALOX12). Typically, SPMs are thought to be formed via consecutive steps of oxidation of polyenoic fatty acids such as arachidonic acid, eicosapentaenoic acid or docosahexaenoic acid. One hallmark of SPM formation is that reported levels of these lipid mediators are much lower than typical pro-inflammatory mediators including the monohydroxylated fatty acid derivatives (e.g., 5-HETE), leukotrienes or certain cyclooxygenase-derived prostaglandins. Thus, reliable detection and quantification of these metabolites is challenging. This paper is aimed at critically evaluating i) the proposed biosynthetic pathways of SPM formation, ii) the current knowledge on SPM receptors and their signaling cascades and iii) the analytical methods used to quantify these pro-resolving mediators in the context of their instability and their low concentrations. Based on current literature it can be concluded that i) there is at most, a low biosynthetic capacity for SPMs in human leukocytes. ii) The identity and the signaling of the proposed G-protein-coupled SPM receptors have not been supported by studies in knock-out mice and remain to be validated. iii) In humans, SPM levels were neither related to dietary supplementation with their ω-3 polyunsaturated fatty acid precursors nor were they formed during the resolution phase of an evoked inflammatory response. iv) The reported low SPM levels cannot be reliably quantified by means of the most commonly reported methodology. Overall, these questions regarding formation, signaling and occurrence of SPMs challenge their role as endogenous mediators of the resolution of inflammation.

Download full text files

Export metadata

Metadaten
Author:Nils Helge SchebbORCiDGND, Hartmut KühnGND, Astrid Stefanie KahntORCiDGND, Katharina M. RundGND, Valerie B. O’Donnell, Nicolas FlamandORCiD, Marc Peters-GoldenORCiD, Per-Johan JakobssonORCiDGND, Karsten-Henrich WeylandtORCiDGND, Nadine RohwerORCiDGND, Robert C. MurphyGND, Gerd GeisslingerORCiDGND, Garret A. FitzGeraldORCiD, Julien HansonORCiDGND, Claes DahlgrenORCiD, Mohamad Wessam AlnouriGND, Stefan OffermannsORCiDGND, Dieter SteinhilberORCiDGND
URN:urn:nbn:de:hebis:30:3-739372
DOI:https://doi.org/10.3389/fphar.2022.838782
ISSN:1663-9812
Parent Title (English):Frontiers in pharmacology
Publisher:Frontiers Media
Place of publication:Lausanne
Document Type:Article
Language:English
Date of Publication (online):2022/03/02
Date of first Publication:2022/03/02
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2023/06/02
Tag:FPR; LC-MS-based lipid mediator analysis; SPM; leukotriene; lipoxin; lipoxygenase; resolution of inflammation; resolvin
Volume:13
Issue:art. 838782
Article Number:838782
Page Number:22
First Page:1
Last Page:22
Institutes:Biochemie, Chemie und Pharmazie
Medizin
Dewey Decimal Classification:5 Naturwissenschaften und Mathematik / 54 Chemie / 540 Chemie und zugeordnete Wissenschaften
6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International